TY - JOUR
AU1 - Herold, Tobias
AU2 - Rothenberg-Thurley, Maja
AU3 - Grunwald, Victoria V.
AU4 - Janke, Hanna
AU5 - Goerlich, Dennis
AU6 - Sauerland, Maria C.
AU7 - Konstandin, Nikola P.
AU8 - Dufour, Annika
AU9 - Schneider, Stephanie
AU1 - Neusser, Michaela
AU1 - Ksienzyk, Bianka
AU1 - Greif, Philipp A.
AU1 - Subklewe, Marion
AU1 - Faldum, Andreas
AU1 - Bohlander, Stefan K.
AU1 - Braess, Jan
AU1 - Wörmann, Bernhard
AU1 - Krug, Utz
AU1 - Berdel, Wolfgang E.
AU2 - Hiddemann, Wolfgang
AU2 - Spiekermann, Karsten
AU2 - Metzeler, Klaus H.
AB - The revised 2017 European LeukemiaNet (ELN) recommendations for genetic risk stratification of acute myeloid leukemia have been widely adopted, but have not yet been validated in large cohorts of AML patients. We studied 1116 newly diagnosed AML patients (age range, 18–86 years) who had received induction chemotherapy. Among 771 patients not selected by genetics, the ELN-2017 classification re-assigned 26.5% of patients into a more favorable or, more commonly, a more adverse-risk group compared with the ELN-2010 recommendations. Forty percent of the cohort, and 51% of patients ≥60 years, were classified as adverse-risk by ELN-2017. In 599 patients <60 years, estimated 5-year overall survival (OS) was 64% for ELN-2017 favorable, 42% for intermediate-risk and 20% for adverse-risk patients. Among 517 patients aged ≥60 years, corresponding 5-year OS rates were 37, 16, and 6%. Patients with biallelic CEBPA mutations or inv(16) had particularly favorable outcomes, while patients with mutated TP53 and a complex karyotype had especially poor prognosis. DNMT3A mutations associated with inferior OS within each ELN-2017 risk group. Our results validate the prognostic significance of the revised ELN-2017 risk classification in AML patients receiving induction chemotherapy across a broad age range. Further refinement of the ELN-2017 risk classification is possible.
TI - Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
JF - Leukemia
DO - 10.1038/s41375-020-0806-0
DA - 2020-03-30
UR - https://www.deepdyve.com/lp/springer-journals/validation-and-refinement-of-the-revised-2017-european-leukemianet-2kDet6Smp0
SP - 3161
EP - 3172
VL - 34
IS - 12
DP - DeepDyve
ER -